$6.67
1.48%
Nasdaq, Mon, Dec 01 2025

ChromaDex Corporation Stock price

$6.67
-0.56 7.75% 1M
-5.06 43.14% 6M
+1.37 25.73% YTD
-0.89 11.77% 1Y
+4.97 292.35% 3Y
+1.65 32.87% 5Y
+5.38 417.05% 10Y
+2.92 77.87% 20Y
Nasdaq, Closing price Mon, Dec 01 2025
-0.10 1.48%

Key metrics

Basic
Market capitalization
$532.3m
Enterprise Value
$468.2m
Net debt
positive
Cash
$64.1m
Shares outstanding
79.6m
Valuation (TTM | estimate)
P/E
27.8 | 45.4
P/S
4.3 | 4.1
EV/Sales
3.8 | 3.6
EV/FCF
22.1
P/B
7.5
Financial Health
Equity Ratio
67.5%
Return on Equity
18.6%
ROCE
25.6%
ROIC
88.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$124.7m | $129.0m
EBITDA
$20.1m | $17.0m
EBIT
$19.3m | $10.8m
Net Income
$20.4m | $11.7m
Free Cash Flow
$21.2m
Growth (TTM | estimate)
Revenue
36.0% | 29.5%
EBITDA
1,456.6% | 99.0%
EBIT
4,218.6% | 39.6%
Net Income
1,271.1% | 36.8%
Free Cash Flow
420.9%
Margin (TTM | estimate)
Gross
63.9%
EBITDA
16.1% | 13.2%
EBIT
15.5%
Net
16.4% | 9.1%
Free Cash Flow
17.0%
More
EPS
$0.2
FCF per Share
$0.3
Short interest
4.2%
Employees
-
Rev per Employee
-
Show more

Is ChromaDex Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,075 stocks worldwide.

ChromaDex Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ChromaDex Corporation forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ChromaDex Corporation forecast:

Buy
91%
Hold
9%

Financial data from ChromaDex Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
125 125
36% 36%
100%
- Direct Costs 45 45
27% 27%
36%
80 80
41% 41%
64%
- Selling and Administrative Expenses 54 54
9% 9%
44%
- Research and Development Expense 5.94 5.94
1% 1%
5%
20 20
1,457% 1,457%
16%
- Depreciation and Amortization 0.78 0.78
7% 7%
1%
EBIT (Operating Income) EBIT 19 19
4,219% 4,219%
15%
Net Profit 20 20
1,271% 1,271%
16%

In millions USD.

Don't miss a Thing! We will send you all news about ChromaDex Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.

Head office United States
CEO Robert Fried
Founded 1999
Website www.niagenbioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today